# University of California, Irvine



### Introduction

- Cardiovascular Disease (CVD) is the leading cause of maternal mortality<sup>2</sup>, and 25% of these cases are preventable<sup>3-5</sup>
- ACOG recently endorsed the California Cardiovascular disease screening algorithm (figure 2) for all pregnant and postpartum women

#### Objectives

We aim to prospectively determine the screen positive and true positive rates for CVD among women across two populations.

## Study Design

Cohort study of a convenience sample of pregnant and postpartum patients from April 2018 to July 2019 at the University of California, Irvine, California and Montefiore Medical Center, Bronx, New York

- Subjects were screened at least once during pregnancy or postpartum
- Patients who were deemed screened positive ('Red Flags', >3-4 moderate risk factors, abnormal physical examination, persistent symptoms) underwent further testing
- The primary outcome was the screen positive rate
- Secondary outcomes were the "true positive" rate and the strength of each of the moderate factors in predicting CVD
- Univariate logistic regression was used to analyze data

# The Heart of the Matter: Initial Application of the California Cardiovascular Disease Toolkit

Senderoff, D., Blumenthal, E., Saturnino, K., Crosland, A., Garg, N., Bernstein, M., Wolfe, D., Hameed, A.

University of California, Irvine; Albert Einstein College of Medicine

Results

- 846 women were screened
- Overall screen positive rate was 8% (5% in California vs. 19% in New York)
- The sites differed as follows:
  - Proportion of African American women (2.7% in California vs 35% in New York, p<0.01)
  - Proportion of substance use (2.7% vs 5.6%, p < 0.04)
- The true positive rate was 1.5% at both sites
  - Several of the screen positive patients in New York did not complete follow up studies
- CVD was confirmed in 30% of women with positive screens with complete follow up
- Combinations of moderate factors were the main driver of screen positive rates in both populations
- Table 1 illustrates predictive potential of the moderate risk factors.





| Table 1. Association of moderate risk factors with positive CVD screen        |                          |          |             |
|---|--------------------------|----------|-------------|
| Risk Factors  | Positive Screen          |          |             |
|   | Odds Ratio (95%<br>C.I.) | p value* | c-statistic |
| Symptoms  |                          |          |             |
| Dyspnea   | 50.3 (25.3-99.9)         | <0.01    | 0.84        |
| Palpitations  | 48.7 (21.6-109.5)        | <0.01    | 0.80        |
| Mild orthopnea  | 41.9 (16.4-107)          | <0.01    | 0.76        |
| Dizziness/Syncope   | 25.2 (10.8-59)           | <0.01    | 0.73        |
| Chest pain  | 24.8 (7.6-80.9)          | <0.01    | 0.70        |
| Asthma unresponsive to<br>therapy   | 17.2 (16.4-107)          | <0.01    | 0.67        |
| Vital Signs   |                          |          |             |
| Systolic Blood Pressure ≥ 140<br>mmHg   | 22.4 (9.6-52.1)          | <0.01    | 0.74        |
| Oxygen Saturation ≤ 96%   | 14.5 (4.2-50.2)          | <0.01    | 0.67        |
| Resting Heart Rate ≥ 110 BPM  | 6.0 (2.2-16.7)           | <0.01    | 0.67        |
| Respiratory Rate ≥ 24   | NA                       | NA       | NA          |
| Risk Factors  |                          |          |             |
| African American  | 27.8 (13.1-59.2)         | <0.01    | 0.73        |
| Chronic hypertension  | 17.0 (8.8-32.7)          | < 0.01   | 0.76        |
| Pre-existing diabetes   | 12.8 (5.9-27.9)          | < 0.01   | 0.73        |
| Age ≥ 40  | 9.8 (4.5-21.7)           | <0.01    | 0.70        |
| Substance Use   | 7.7 (3.5-17.2)           | <0.01    | 0.67        |
| Pre-Pregnancy Obesity (BMI ≥ 35)  | 5.9 (3.1-11.2)           | <0.01    | 0.71        |
| History of Chemotherapy   | 4 (0.2-43.1)             | < 0.01   | 0.66        |
| NA = Not Applicable (no RR> 24 was recorded as a moderate factor in screening |                          |          |             |

\*p value determined by univariate logistic regression

2015.









Society for Maternal Fetal Medicine

#### Conclusion

• We report CVD screen positive and true positive rates among obstetrical populations at two academic tertiary care centers serving diverse populations.

• We identify the most predictive moderate factors that may help simplify the CVD toolkit algorithm for ease of use.

• Our study is limited by lack of follow up studies in screen positive patients, however suggests that in screen positive patients the rate of true CVD is substantial.

• This is an initial attempt to test the CVD algorithm.

• Data may be used to design a larger multicenter investigation to validate the CVD algorithm.

#### References

1. ACOG Practice Bulletin Number 212, Pregnancy and Heart Disease, Vol 133, No 5, May 2019.

2. Creanga AA, Berg CJ, Syverson C, Seed K, Bruce FC, Callaghan WM. Pregnancy-related mortality in the United States, 2006-2010. Obstet Gynecol. 2015;125(1):5-12.

3. Hameed A, Lawton E, McCain C, et al. Pregnancy-related cardiovascular deaths in California: Beyond peripartum cardiomyopathy. American Journal of Obstetrics and Gynecology.

4. Gunderson EP, Croen LA, Chiang V, Yoshida CK, Walton D, Go AS. Epidemiology of peripartum cardiomyopathy: incidence, predictors, and outcomes. Obstetrics and Gynecology. 2011;118(3):583-591. 5. Kuklina EV, Callaghan W. Chronic heart disease and severe obstetric morbidity among hospitalisations for pregnancy in the USA: 1995-2006. BJOG : an international journal of obstetrics and gynaecology. 2011;118(3):345-352.